Agilent Technologies Target Oral Cancer with New Collaboration
Agilent Technologies (California, USA) is to collaborate with the University of Queensland Centre for Clinical Research (Brisbane, Australia) to further understanding of the genomic differences governing oral cancer. According to the National Center for Biotechnology Information, oral cancer is the sixth most prevalent cancer worldwide.
Agilent Technologies (California, USA) is to collaborate with the University of Queensland Centre for Clinical Research (Brisbane, Australia) to further understanding of the genomic differences governing oral cancer. According to the National Center for Biotechnology Information, oral cancer is the sixth most prevalent cancer worldwide.
Oral potentially malignant lesions (OPMLs) are visibly altered precursors of many oral squamous cell carcinomas (OSCCs), but the reason for the transition is not known. The researchers involved hope to implement next-generation sequencing and data analysis to identify the molecular basis of the transition and therefore open up new targets for therapeutic drugs. Camile Farah, Head of the Oral Oncology Research Programme, said: "Our collaboration and support from Agilent will accelerate our work in this important area of clinical research."
For more information visit: www.uqccr.uq.edu.au
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
